Ezipect

Quick links to important sections

Ezipect

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ezipect

Quick Facts

Property Description
Active Ingredients Bromhexine hydrochloride, Diphenhydramine hydrochloride
Form Oral solution (Syrup)
Pharmacological Class Mucolytic Agent and H1 Antihistamine
Common Use Relief of respiratory congestion and associated allergic symptoms
Origin Synthetic

What Type of Medicine is Ezipect?

Ezipect is defined as a synthetic, fixed-dose combination product classified as both a mucolytic agent and an H1 Antihistamine. This dual classification defines its function as a multi-component preparation designed to provide comprehensive support for symptoms related to respiratory tract congestion and associated allergic responses. The medicine is commonly utilized in scenarios where a patient requires relief from both thickened mucus and the symptomatic irritation of a cold. Unlike single-ingredient remedies, Ezipect integrates two distinct pharmacological actions into one formulation.

Ezipect Composition and Dosage Form

The formulation features two core active ingredients: Bromhexine hydrochloride and Diphenhydramine hydrochloride. The medicine is supplied as an oral solution (syrup) for the oral route of administration. The Diphenhydramine component is classified as an H1 receptor antagonist. This compound helps calm symptoms like sneezing and nasal discharge often associated with respiratory irritation. This specific composition positions the medicine to address two facets of respiratory distress simultaneously: the physical burden of thickened phlegm and the symptomatic irritation driven by the body's release of histamine. Bromhexine functions to reduce the viscosity of tenacious respiratory secretions. This means the medicine helps make thick phlegm thinner and easier to clear from the airways.

How Ezipect Combines Two Different Actions

The therapeutic advantage of Ezipect is rooted in its dual physiological action for managing complex respiratory conditions. The Bromhexine component acts as the mucolytic agent by reducing the viscosity of sticky bronchial secretions, thereby facilitating the removal of thick phlegm and aiding a productive cough. Concurrently, the Diphenhydramine component functions as the antihistamine, which helps to calm symptomatic irritation and allergy by blocking histamine activity in the body. This fixed combination provides a broader approach by simultaneously addressing both the physical burden of secretions and the symptomatic response that often accompanies congestion in the airways.

What side effects are possible with Ezipect?

Possible Side Effects and Safety Information

The safety profile for Ezipect, which combines a mucolytic (Bromhexine) and an antihistamine (Diphenhydramine), is derived from the documented adverse reactions and regulatory classifications of its individual components.


Official Adverse Reaction Classifications

Adverse reactions are formally categorized by System-Organ Classes (SOCs), affecting systems such as the Nervous System, Gastrointestinal System, Immune System, and Skin.

Classification Examples of Documented Reactions
Common / Expected Sedation, Drowsiness, Dizziness, Dry mouth, Nausea, Vomiting
Uncommon to Rare Diarrhea, Abdominal pain, Hypersensitivity reactions, Rash, Urticaria
Not Known Anaphylactic reactions (including shock), Severe Cutaneous Adverse Reactions (SCARs), Convulsions, Bronchospasm

Documented Serious Reactions and Constraints

The most significant documented adverse reactions include rare, serious events such as Anaphylactic Reactions and SCARs (like Stevens-Johnson syndrome) associated with the bromhexine component. The antihistamine component carries a documented risk of severe effects such as Convulsions and blood disorders (e.g., Agranulocytosis).

Safety Constraints and Vulnerable Populations:

  • Central Nervous System (CNS) Effects: Regulatory labels note the potential for additive effects when this medicine is used with alcohol or other CNS depressants.
  • Pediatric Safety: The medicine is contraindicated in children younger than two years of age due to safety concerns. In some young children, it may cause excitation rather than sedation.
  • Older Adults: This population is noted to be at higher risk for side effects such as dizziness, sedation, and hypotension.
  • Organ Impairment: Caution is required in patients with pre-existing severe hepatic or renal impairment due to potential reduced clearance of the active components.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory information regarding Ezipect overdose is largely centered on the systemic effects of the Diphenhydramine component, which necessitate immediate, mandated emergency action. Exposure to higher than recommended doses is documented as potentially serious and life-threatening.


Documented Overdose Manifestations

Official labeling describes that overdose may present with a dangerous spectrum of Central Nervous System (CNS) effects. These range from CNS excitation (agitation, hallucinations, delirium, seizures) to severe CNS depression (somnolence, stupor, coma). Other documented signs include the Anticholinergic Syndrome manifestations, such as a rapid heart rate (tachycardia), fixed and dilated pupils, high fever (hyperpyrexia), and difficulty urinating.

Severe Outcomes and Emergency Actions

Severe outcomes explicitly listed in regulatory documents include ventricular dysrhythmias, QRS widening, circulatory collapse, respiratory failure, and death. Infants and children face an increased risk of severe, life-threatening side effects, including convulsions.

Immediate medical attention is mandated if an overdose is suspected or if the patient is experiencing any severe symptoms, such as having a seizure, difficulty breathing, or cannot be awakened. Regulatory guidance requires calling emergency services or Poison Control immediately. Treatment is officially described as symptomatic and supportive, requiring rigorous hospital monitoring, including continuous Electrocardiogram (ECG) observation. No specific antidote is known.

Therapeutic Uses of Ezipect

What Ezipect Treats: Main Uses and Benefits

Ezipect is commonly used to address the burden of conditions, such as the common cold and acute bronchitis, that are accompanied by excessive, thick mucus production. The medication may assist with symptoms related to excessive, thick mucus by helping to ease the difficulty of expectoration and may assist with managing symptoms of a chesty cough. This therapeutic approach is considered relevant in conditions where the symptoms relate to localized functional stress involving the lungs and airways.

The second therapeutic domain addresses the irritative and allergic manifestations that frequently cluster with congestion, including sneezing, a runny nose (rhinorrhea), and an itchy throat. Diphenhydramine, one of the components, is used to relieve such common cold and allergy symptoms. This action may help address symptoms related to inflammatory or irritative states and contributes to easing the overall symptom load.

The primary indications for this product involve conditions that cause both excessive mucus and allergic irritation, such as certain manifestations of the common cold, acute bronchitis, and the flu. The combination is relevant for managing symptoms related to both chest congestion and associated symptomatic irritation. It supports the patient during difficult episodes by easing distress.

“The combination is relevant for managing symptoms related to both chest congestion and associated symptomatic irritation.”


Quick Fact: Symptomatic Support for Combined Manifestations
Key Use Symptomatic relief for thick mucus and allergic irritation.
Mucus Symptom Management May assist with symptoms of excessive, thick mucus.
Irritation Symptom Management Is applied in addressing sneezing, runny nose, and itching of the throat or nose.

Regulatory References

  1. NIH MedlinePlus overview of Diphenhydramine use

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ezipect — Official Regulatory Information

The following outlines the official population eligibility and non-eligibility for Ezipect (Bromhexine hydrochloride and Diphenhydramine hydrochloride) strictly based on governmental regulatory documentation.


Eligibility Scope

Classification Population or Condition
Contraindicated Neonates or Premature Infants
Contraindicated Nursing Mothers (Lactation)
Contraindicated Patients with known hypersensitivity to Bromhexine, Diphenhydramine, or excipients
Not Recommended Pregnancy (First Trimester)
Not Recommended Children under 2 years old
Use with Caution Severe liver disease or severe renal failure
Use with Caution History of gastric ulceration or stenosing peptic ulcer
Use with Caution Narrow-angle glaucoma, prostatic hypertrophy, or bladder-neck obstruction
Use with Caution History of bronchial asthma or hypertension

Official Eligibility Summary

Official regulatory documents establish an absolute prohibition for the use of Ezipect in neonates, premature infants, and nursing mothers. Use is also contraindicated for anyone with a known allergy to the active ingredients. The medicine is not recommended for women in the first trimester of pregnancy or in children under 2 years old. Use requires explicit caution in populations with pre-existing conditions such as severe hepatic or renal impairment, narrow-angle glaucoma, or prostatic hypertrophy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Ezipect based on its two active components, Bromhexine hydrochloride and Diphenhydramine hydrochloride.

Formal Restrictions and Additive Effects

Category Interacting Substances or Products Regulatory Constraint or Outcome
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs) Co-administration is prohibited due to the risk of prolonging and intensifying the anticholinergic effects of Diphenhydramine.
Pharmacodynamic Interaction Central Nervous System (CNS) Depressants Additive pharmacological effects increase the risk of CNS depression and enhanced drowsiness.
Substance Interaction Alcohol (Ethanol) Officially documented to have additive CNS depressant effects, which increases the risk of drowsiness.

Other Documented Interaction Patterns

Co-administration with Other Anticholinergic Drugs may result in an intensification of anticholinergic effects. Furthermore, the Bromhexine component of Ezipect is officially documented to influence the distribution of certain Antibiotics (including Amoxicillin, Erythromycin, and Cefuroxime) by enhancing their penetration into bronchial secretions, a regulatory-cited effect. The label also contains a restriction regarding the co-administration of the Bromhexine component with Cough Suppressants (Antitussives), as this may impair the cough reflex and potentially lead to the accumulation of mucus in the respiratory tract. For patients with severe hepatic impairment, regulatory texts note that the clearance of the Bromhexine component or its metabolites may be reduced, a factor that may heighten the risk of documented interactions.

Mechanism of Action

Modulation of Mucus Viscosity


Ezipect engages mechanisms that regulate the physical properties of bronchial secretions, primarily by acting as a mucolytic agent. This process initiates a cascade where the compound breaks down the long mucopolysaccharide fibers and activates the synthesis of less viscous serous mucus, resulting in the modification of tracheobronchial fluid dynamics and reduced viscosity of tracheobronchial secretions.

Enhancement of Mucociliary Clearance


This compound affects systems where specific transmitters or mediators dominate, modulating signaling patterns driven by distinct signaling sequences. It promotes a secretomotoric effect that activates the ciliary epithelium lining the airways. The physiological outcome is the adjustment of ciliary rhythmicity, which mechanically facilitates transport and clearance of secretions within the pulmonary system.

Dosage and Administration Information

Instruction Map: Official Administration Guidelines

Ezipect is a fixed-combination oral solution whose administration is governed by established protocols for its constituent active ingredients, Bromhexine and Diphenhydramine. These protocols define the standardized pattern of use, focusing solely on the procedural aspects of intake.


Administration Scope

Feature Official Usage Instruction
Route of administration: Administration is exclusively through oral ingestion of the liquid formulation.
Dosing schedule (Adults): The standard regimen is typically defined by a dose volume equivalent to one to two 5 mL spoonfuls per administration.
Timing in relation to meals: The prescribed usage pattern is to administer the solution with food or shortly after a meal.
Age-group administration rules: The standard adult dosing schedule is applicable to patients 12 years of age and over.
Missed-dose rules: The procedure for a missed dose is to skip the omitted dose and resume the regular scheduled administration, avoiding the ingestion of a double quantity.
Special procedural conditions: Use is restricted to short-term symptomatic management, generally not exceeding 14 days without professional reassessment. Dosage adjustments are a necessary principle for patients with documented severe hepatic or renal impairment.

Instruction Classifications (High-Level)

The protocol establishes that the administration method is Oral (Liquid/Syrup), with a Daily frequency pattern administered three to four times per day. The usage is constrained as time-bound and condition-dependent, requiring dose modification in the presence of specific organ impairment.


Connection to the Overall Use Protocol

The protocol defines a structured usage pattern centered on the oral administration of a measured dose at a prescribed three-to-four-times-daily frequency. This structure dictates that the use is time-limited to short courses and mandates that specific patient populations be managed under an adjusted dosing principle, all without referencing the medicine's mechanism or therapeutic effect.

Recent Clinical Evidence

Research evidence / Overview of studies for Ezipect

Evidence for use in Acute Bronchitis

Ezipect was studied for trials assessing short-term or episodic symptom patterns related to Acute Bronchitis, a condition characterized by fluctuating or episodic manifestations. Research examined these outcomes using short-term randomized controlled trials (RCTs). These studies focused on measuring patient-reported outcomes describing perceived discomfort, outcomes related to physical discomfort, and functional axes like daily functioning or activity level.

Studies report how symptoms evolved in the observed populations during the study period. Findings described patterns observed in the studies, and research highlights changes measured during the short follow-up time. However, evidence is limited regarding long-term effects. Research exploring short-term symptom changes provides limited insight into long-term outcomes, and data for certain groups, such as individuals with pre-existing lung conditions, remain insufficient.

Evidence for use in Chronic Obstructive Pulmonary Disease (COPD)

Research examined Ezipect in individuals with Chronic Obstructive Pulmonary Disease (COPD), a condition marked by functional limitations and periods of heightened symptoms. These studies primarily involved controlled clinical trials and observational cohorts. The outcomes monitored physiological strain or stress, functional axes, and outcomes related to episodic or acute changes. Data show patterns related to measured physiological parameters, such as lung function tests, during the study period.

What is still uncertain about Ezipect

The long-term effects are not fully established. While data show patterns related to measured outcomes over the intermediate term, comparative evidence is lacking for extended periods beyond the planned duration of the main clinical trials. Results apply only to the populations studied, which often excluded individuals with severe comorbidities. Sample sizes were modest in some subgroup analyses, meaning certainty remains low in certain areas. Research provides context and describes group patterns but not individual predictions for Ezipect.

Frequently Asked Questions (FAQ)

Common questions about Ezipect (FAQ)

Q: How long do the effects of Ezipect usually last?

The administration schedule established in official regulatory documents typically involves taking the medicine three to four times per day. This usage pattern suggests that the medicine's therapeutic effects are generally sustained over several hours. Regulatory documents recommend following the administration schedule defined by a healthcare professional.

Q: Can Ezipect be taken at the same time as cold and flu medicine?

Regulatory documents describe a risk of enhanced drowsiness and additive central nervous system (CNS) depression when Ezipect is combined with other CNS depressants. Since many cold and flu medicines contain ingredients that can also cause drowsiness, combining them may intensify these effects. The official information provides details on specific drug categories that may pose an additive risk.

Q: Are there any specific food or drinks that should be avoided when taking Ezipect?

Official information documents an additive CNS depressant effect when Ezipect is used alongside alcohol (ethanol), which can increase the risk of drowsiness. Regarding food, regulatory protocols establish the usage pattern as being taken with food or shortly after a meal. No specific food types are listed for avoidance in the formal interaction constraints.

Q: Why is Ezipect sometimes compared to other similar cough or congestion medicines?

Ezipect is formally defined as a fixed-dose combination product. Its structure contains both a mucolytic agent (to thin mucus) and an H1 Antihistamine (to manage allergic symptoms). This dual action positions it pharmacologically alongside single-ingredient medicines that target just one of these symptoms, leading to comparison in the market.

Q: Can Ezipect cause sleeplessness or difficulty falling asleep?

While regulatory safety information lists sedation and drowsiness as common effects, there are documented cases where the medicine may cause paradoxical excitation rather than sedation, particularly in some young children. Official documents address adverse effects, and any unexpected reaction is a reason to seek professional guidance.

Q: Does taking Ezipect affect blood pressure or heart rate?

Official safety documents list hypotension (low blood pressure) as a potential side effect. This risk is specifically noted to be higher in older adults, who may also experience increased dizziness and sedation. The medicine’s effect on heart rate is not explicitly detailed as a common concern in the regulatory profile.

Q: What are the inactive ingredients contained in the Ezipect tablet/capsule?

Ezipect is supplied as an oral solution (syrup), not a tablet or capsule. The full list of inactive ingredients, known as excipients, is documented in the official regulatory product information.

Q: What is the general safety classification of Ezipect according to major health bodies?

Regulatory bodies classify the safety of Ezipect by defining lists of patient populations and conditions. These documents establish clear limits, specifying where the medicine is contraindicated (absolutely forbidden), not recommended, or requires caution during use.

Q: How is Ezipect typically eliminated from the body?

Pharmacokinetic studies, which describe how the body processes the medicine, show that the active components are primarily metabolized by the liver. They are then eliminated from the body by the kidneys. This process explains why caution is required for patients with severe hepatic or renal impairment.

Q: Are there different strengths or forms of Ezipect available?

The medicine is approved and marketed by regulatory bodies as a specific strength of oral solution (syrup). The official product information only details this one approved strength and form for patient use.

Q: Is Ezipect available over the counter, or is it prescription-only?

Ezipect is classified by regulatory authorities in most regions as a prescription medicine. This means it is not available for purchase over the counter and must be obtained via a valid prescription from a licensed healthcare professional.

Q: How quickly does Ezipect typically start working after I take it?

Pharmacokinetic studies indicate that the concentration of the medicine in the body, which correlates with the onset of effect, is typically reached within one to two hours following oral administration. Individual response times may vary.

Q: Does Ezipect interact with common pain relievers like ibuprofen or acetaminophen?

Official regulatory documents define specific substances that require formal interaction warnings. These documents do not specifically list common non-opioid pain relievers such as ibuprofen or acetaminophen as drugs with which Ezipect has a known interaction constraint.

Q: Is it considered safe to drive or operate machinery while using Ezipect?

Official product labels include a clear warning regarding activities requiring full concentration. Due to the potential for sedation, dizziness, and drowsiness, individuals are advised to avoid driving or operating heavy machinery while using this medicine.

Q: Where can I find the official regulatory information about Ezipect?

The full, official patient information leaflet (PIL) or consumer medicine information (CMI) can be found on the websites of the government regulatory bodies that originally approved the medicine. These documents provide the definitive, authorized information.

Q: Does Ezipect have a known risk of addiction or misuse?

Official regulatory documents include standard sections to address drug abuse and dependence. For Ezipect, these documents do not contain warnings or constraints related to abuse, misuse, or dependence.

Q: Does Ezipect contain gluten, lactose, or other common allergens?

Regulatory documents list all excipients (inactive ingredients) used in the formulation. Official warnings specify if the product contains common allergens or substances like lactose, sucrose, or ethanol that may be relevant to certain allergies or intolerances.

Q: What should I do if my symptoms do not improve while taking Ezipect?

Official patient information advises that if symptoms worsen, fail to improve, or if new or unexpected symptoms occur, the patient should refer back to their healthcare professional for assessment.

Q: Can I take Ezipect if I am taking supplements like vitamins or herbal products?

The list of documented interactions in regulatory documents focuses primarily on interactions with prescription and over-the-counter medicines. Caution is generally described in official documents when combining with non-standard substances.

Q: Are there any known interactions between Ezipect and caffeine?

Official regulatory documents do not contain specific warnings or constraints regarding the co-administration of Ezipect and caffeine. Documented interactions primarily focus on substances that cause CNS depression.

Q: Does Ezipect have a 'black box' warning in its regulatory documents?

Based on the regulatory profile of its active ingredients, Ezipect's official label does not include a Boxed Warning. This is the most stringent type of warning mandated by the U.S. FDA to alert users to serious safety concerns.

Q: Can Ezipect affect my ability to feel pain?

Ezipect is pharmacologically classified as a mucolytic and an H1 antihistamine. It is not described in official documents as having any analgesic (pain-relieving) properties or uses.

Q: Is it okay to stop taking Ezipect suddenly?

Since Ezipect is generally prescribed for short-term, symptomatic use, official product information does not include any special instructions or warnings about needing to gradually reduce the dose before discontinuing the medicine.

How should Ezipect be stored and disposed of?

Ezipect (Bromhexine HCl / Diphenhydramine HCl) oral solution must be stored according to specific regulatory requirements to maintain its stability. The medicine must be kept at room temperature, generally specifying limits below 30 C or 25 C. It is mandatory to keep the product in its original container, ensure the bottle is tightly closed, and protect it from light and moisture. For safety, the medicine must be stored out of the reach and sight of children.

Expired or unused Ezipect should be disposed of responsibly. The preferred method is using a community drug take-back program. If this is not an option, the medicine should be mixed with an undesirable substance, placed in a sealed container, and thrown into the household trash. It should not be disposed of via household wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ezipect found in:

A-Z Index: